Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - Pharmaceutical Development - September 19, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/19/17 - ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 10:00 a.m. Eastern Time i
9/19/17 - Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept development and commercialization collaboration agreement with Celgene Corporation, originally executed on February 20, 2008. Sotatercept shows...
9/19/17 - Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, today announced that results from a Phase 2 clinical trial evaluating two concentrations of its drug candidate A-101 for the treatment of facial seborrheic keratosis lesions have been published in the journal Dermatologic Surgery. The FDA s Prescription Drug User Fee Ac
9/19/17 - AgeneBio Receives NIH Grant to Initiate Phase 3 HOPE4MCI Trial to Treat MCI Due to Alzheimer's Disease
This grant builds on the previous NIH grant for the HOPE4MCI trial that established a public-private partnership among the NIA, Johns Hopkins University, and AgeneBio for the HOPE4MCI trial. "With the award of this additional funding from the NIH, we will immediately initiate the Phase 3 trial start-up with an initial cohort of clinical sites and
9/19/17 - Agilent Announces Expanded Use of Cancer Diagnostic in the United States; .Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications
SANTA CLARA, Calif. Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which pat
9/19/17 - Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal Assay
SANTA CLARA, Calif.- Agilent Technologies Inc. has announced that it has obtained 510 clearance from the U.S. Food and Drug Administration for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization assay for diagnostic use. Previously available only in Europe, U.S. clinical genetic scientists can now use this assay to help i
9/19/17 - Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive Officer Dr. David Horn Solomon and Chief Operations Officer Clive Richardson will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday September 26, 2017 in New York City. To access the live webcast of t
9/19/17 - Amgen and Allergans anti-cancer biosimilar Mvasi receives FDA approval [All Iraq News Agency (AIN)]
Co-developed by Amgen and Allergan, Mvasi is the first anti-cancer biosimilar to be approved by the FDA and is largely similar to Avastin. Amgen research and development executive vice-president Dr Sean E. Harper said: The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first anti-cancer biosimilar..
9/19/17 - AMICUS THERAPEUTICS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On September 19, 2017, Amicus Therapeutics, Inc. issued a press release announcing that the U.S. FDA has granted Fast Track Designation for Amicus Therapeutics' Migalastat for Treatment of Fabry Disease. A copy of this press release is attached hereto as Exhibit 99.1. Description 99.1 Press Release dated September 19, 2017 titled " U.S. FDA Grants
9/19/17 - Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis. The Company recently began a Phase 2 clinical study, the CENTAUR trial, to evaluate the safety and efficacy of AMX003
9/19/17 - Arcus Biosciences Appoints Kate Falberg to Its Board of Directors [National News Agency (Lebanon)]
Ms. Falberg brings extensive financial, strategic and operational experience in the life sciences industry. Ms. Falberg currently serves on the boards of Aimmune Therapeutics, Axovant Sciences, UroGen Pharma and The Trade Desk, and recently served on the Board of Directors of Medivation until its acquisition by Pfizer. Ms. Falberg holds B.A. and M.
9/19/17 - Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, will hold a conference call to discuss an update on the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of...
9/19/17 - Atossa Genetics, Endoxifen Phase I Results and Pipeline Review
NEW YORK, NY/ ACCESSWIRE/ September 19, 2017/ Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive report with no obligation on Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to
9/19/17 - Australian-First Personalised Medicine Clinical Trial for Children With Most Aggressive Cancers
The University of New South Wales issued the following news release:. Zero Childhood Cancer, one of the world's most comprehensive child cancer personalised medicine studies, has been launched by Children's Cancer Institute and the Kids Cancer Centre at Sydney Children's Hospital, Randwick. In an Australian first, scientists from 13 leading Austral
9/19/17 - Bayer receives FDA approval for Copanlisib in adults with relapsed follicular lymphoma after two prior systemic therapies
Release date- 18092017- Berlin- Bayer announced today that the U.S. Food and Drug Administration has approved copanlisib under the brand name Aliqopa 60 mg vial for injection for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. The FDA granted approval under the accelerated a
9/19/17 - Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism
Release date- 18092017- Berlin- Bayer AG announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion to update the label for its oral Factor Xa inhibitor Xarelto to include a 10 mg once daily dose for the extended prevention of recurrent venous thromboembolism. The final Eu
9/19/17 - BERG Broadens Relationship With The Department Of Defense (DoD) Center For Prostate Disease Research With New Predictive Biomarker Test For Prostate Cancer
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the completion of clinical validation for a new predictive diagnostic test that can improve detection of prostate cancer. This new development is the result of BERG's long-standing Cooperative Research and Development Agreement wit
9/19/17 - BioLife Solutions CryoStor Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin?
BioLife Solutions, Inc., the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that Cellular Biomedicine Group, a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies..
9/19/17 - Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that data for its drug candidate CB-839, an orally bioavailable glutaminase inhibitor, will be presented a
9/19/17 - Cancer Immunotherapy Market Research, Development, Enabling Innovation, Advancements in Technology to Offer Improved Treatments
"Cancer Immunotherapy Market" Latest industry research report on Cancer Immunotherapy Market: Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts.. This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their pric
9/19/17 - Cardiac Pacemaker Market 2022 Top Market Player - Medtronic plc., Pacetronix ltd., SORIN Group, Medico S.p.A., OSCOR Inc.
Market Research Future adds new report of EURoeGlobal Cardiac Pacemaker Market Research Report- Forecast To 2022 EUR it contains Company information, geographical data and Table of Content. Some of the key players in this market are: Medtronic plc. Jude Medical Inc. Boston Scientific Corporation BIOTRONIK SE& Co. KG Lepu Medical Technology Co ltd..
9/19/17 - Chinese Pharmaceutical Market Forecast 2017-2027
Visiongain, a research firm, issued the following report:. The Chinese Pharmaceutical market is expected to grow at a CAGR of 12.3% in the second half of the forecast period. The Chinese Pharmaceutical market reached $145.4 bn in 2016, dominated by the Cardiovascular therapy area which held 13.6% share of the market.
9/19/17 - CHMP backs maintenance therapy for Tesaro`s Zejula [Arab Finance (Egypt)]
Tesaro picked up an FDA approval for its drug in March, and claims it has become the most widely-prescribed PARP inhibitor despite reaching the market almost three years after Lynparza. Last month however AZ and Merck won an all-comer indication from the FDA for their drug, plus a green light for an improved formulation, that puts it back in conten
Pharmaceutical companies and the federal government have agreed to develop and "fast track" non-opioid pain medication for patients and alternative treatments for people battling addiction, Gov. The work will be done in collaboration with the National Institutes of Health and the Food and Drug Administration, Christie said. The announcement followe
9/19/17 - ContraVir Pharmaceuticals Announces Participation at the Discovery on Target 2017 Conference in Boston
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will be featured at a symposium discussion titled Targeting HBV.. Robert T. Foster, PharmD, PhD, Chief Scientific Officer of ContraVir, will make an oral presentation entitled,
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement